Sheila Gujrathi - Jun 10, 2021 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ Tighe Reardon, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jun 10, 2021
Transactions value $
$0
Form type
3
Date filed
6/10/2021, 07:06 PM
Next filing
Oct 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding JANX Common Stock 105K Jun 10, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Stock Option (right to buy) Jun 10, 2021 Common Stock 57.6K $10.59 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in a series of 24 successive equal monthly installments measured from May 14, 2021. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.